Weiner David B.'s Form 4 filing
Inovio Pharmaceuticals, Inc.INO · filed Feb 28, 2023
- Accession no.
- 0001055726-23-000004
- Filed
- Feb 28, 2023
- Trade date
- Feb 26-27, 2023
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 3 non-derivative transactions and 4 derivative transactions. Open-market sales total $14.9K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Weiner David B.CIK 0001669080 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 26, 2023 | Common Stock | MOption exerciseAcquired | +11,667 | –F1 | – | 904,292 | Direct | |
| Feb 26, 2023 | Common Stock | MOption exerciseAcquired | +11,667 | –F2 | – | 915,959 | Direct | |
| Feb 27, 2023 | Common Stock | SSaleDisposed | −11,668 | $1.28 | −$14,935.04 | 904,291 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 26, 2023 | Common Stock | MOption exerciseDisposed | −11,667 | $0.00 | $0 | 11,666 | Direct | |
| Feb 26, 2023 | Common Stock | MOption exerciseDisposed | −11,667 | $0.00 | $0 | 23,333 | Direct | |
| Feb 27, 2023 | Common Stock | AGrant or awardAcquired | +60,000 | $0.00 | $0 | 60,000 | Direct | |
| Feb 27, 2023 | Common Stock | AGrant or awardAcquired | +35,000 | $0.00 | $0 | 35,000 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
Each restricted stock unit represents a contingent right to receive one share of common stock. On February 26, 2021, the reporting person was granted 35,000 restricted stock units, vesting as follows: 11,667 shares vested on February 26, 2022; 11,667 shares vested on February 26, 2023; and 11,666 shares will vest on February 26, 2024. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both.
Referenced by the price of 1 transaction in Table I.
- F2
Each restricted stock unit represents a contingent right to receive one share of common stock. On February 26, 2022, the reporting person was granted 35,000 restricted stock units, vesting as follows: 11,667 shares vested on February 26, 2023; 11,667 shares will vest on February 26, 2024; and 11,666 shares will vest on February 26, 2025. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both.
Referenced by the price of 1 transaction in Table I.